Active — Not RecruitingPhase 1/2

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

United States8 participantsStarted 2020-09-10

Plain-language summary

The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 46 people will take part in this study conducted by investigators at the University of Iowa.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Positive HBV surface antigen (indicative for chronic hepatitis B or recent acute hepatitis B).
✕. Negative HBV surface antigen but positive HBV total core antibody (indicative for resolved hepatitis B infection or occult hepatitis B) and detectable copies of HBV DNA by PCR (detectable HBV DNA copies suggest occult hepatitis B).

What they're measuring

Number of Participants With Dose Limiting Toxicities (DLTs)

Timeframe: 14 weeks

Pathologic Tumor Necrosis Rate

Timeframe: 14 weeks

Trial details

NCT IDNCT04599062

SponsorJohn Rieth

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-07

Results submitted2023-04-20

View on ClinicalTrials.gov More Soft Tissue Sarcoma trials